---
layout: default
title: Tremelimumab
parent: 僅模型預測 (L5)
nav_order: 449
evidence_level: L5
indication_count: 10
---

# Tremelimumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Tremelimumab: From Hepatocellular Carcinoma/NSCLC to Diabetic Cataract

## One-Sentence Summary

Tremelimumab is an anti-CTLA-4 immune checkpoint inhibitor, currently used in combination regimens for hepatocellular carcinoma and non-small cell lung cancer.
The TxGNN model predicts it may be effective for **Diabetic Cataract**, with a prediction score of **98.49%**,
but currently **0 clinical trials** and **0 publications** support this direction, and the drug is not marketed in Denmark.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | No Danish marketing authorisation on file; per background pharmacology, approved elsewhere for hepatocellular carcinoma / non-small cell lung cancer (combination therapy) |
| Predicted New Indication | Diabetic Cataract |
| TxGNN Prediction Score | 98.49% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data has not been formally documented for this evidence pack (data gap). Based on background pharmacology, tremelimumab is an anti-CTLA-4 monoclonal antibody that activates T-cells to enhance anti-tumour immune response, and is currently used in combination oncology regimens for hepatocellular carcinoma and non-small cell lung cancer.

Diabetic cataract results from lens protein glycation, polyol pathway activation, and oxidative stress secondary to chronic hyperglycemia — a metabolic and structural process with no known intersection with CTLA-4/T-cell activation pathways.

The evidence pack's own mechanistic assessment concludes that this prediction **lacks biological plausibility**: immune checkpoint inhibitors are known to *cause* immune-related ocular adverse events (e.g., uveitis) rather than treat lens opacification, and there is no mechanism by which T-cell activation would reverse or prevent cataract formation.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Denmark Market Information

Tremelimumab has no marketing authorisation on file in Denmark (0 licences; market status: not marketed).

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Immunotherapy (anti-CTLA-4 checkpoint inhibitor) — not a conventional cytotoxic agent |
| Myelosuppression Risk | Low — checkpoint inhibitors are not typically directly myelosuppressive; principal risk is immune-related adverse events, including immune-related ocular events (e.g., uveitis) noted in the mechanistic rationale |
| Emetogenicity Classification | Please refer to the Summary of Product Characteristics (SmPC) — no structured emetogenicity data on file |
| Monitoring Items | Monitoring for immune-related adverse events (endocrine, hepatic, GI, dermatologic), liver and renal function; ophthalmologic monitoring given the noted potential for immune-related eye events |
| Handling Protection | Not a conventional cytotoxic agent; standard oncology biologic infusion precautions apply rather than classic cytotoxic drug handling protocols |

## Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a high TxGNN similarity score, this candidate has zero clinical trials, zero literature support, and evidence level L5 (model prediction only). The evidence pack's own mechanistic rationale explicitly states the drug-disease link lacks biological plausibility, and the drug carries a Blocking data gap on SmPC warnings/contraindications (DG001) and a High-severity gap on MOA documentation (DG002).

**To proceed, the following is needed:**
- Resolve DG001: TFDA/Danish SmPC warnings and contraindications (blocking gap)
- Resolve DG002: formal mechanism-of-action documentation via DrugBank or manufacturer labeling
- Independent preclinical/mechanistic validation of any plausible drug-disease link before further development
- Given the documented lack of biological plausibility, deprioritize this candidate unless new mechanistic or experimental evidence emerges
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

